Prevalence of Neuropathic Pain in Radiotherapy Oncology Units

Mañas, A; Monroy, Jose Luis; Ramos, A. Alia; Cano, Carmen; López-Gómez, V.; Masramon, Xavier; Pérez, María

doi:10.1016/j.ijrobp.2010.05.047

Cited by 28 publications

(24 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…and results from the following questionnaires: the Spanish version of the short form of the Brief Pain Inventory (BPI-SF) validated in cancer patients [30], the Hospital Anxiety and Depression Scale (HADS) [31], the Spanish version of the Medical Outcomes Study Sleep (MOS-Sleep) Scale validated in neuropathic patients [32] and the Spanish validated 12-item short form (SF-12) Health Survey [33]. All questionnaires used are described in the published original study [28].…”

Section: Methodsmentioning

confidence: 99%

“…To meet this challenge, they must be aware of the prevalence of NP in their units and the frequency with which cancer pain is inadequately managed. Therefore, we conducted a study [28] to fi nd out the prevalence of NP among cancer outpatients visiting RT units and the analgesic treatment currently used in these patients. The study [28] showed 31% prevalence and a signifi cant increase in treatment-satisfi ed patients with the current vs. previous treatment, with the major difference between treatments being a 6-fold increase in anticonvulsants (2-fold increase in gabapentin and 10-fold in PGB).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Few previous studies have addressed the relation between treatment-related neuropathic pain and sleep quality of breast cancer patients [26,27]. In a study from Israel, assessing the relationship between symptom clusters and chemotherapy-induced neuropathic pain in a sample of 40 patients treated with paclitaxel, the authors found that the "high cluster group" included patients who reported both high levels of pain with neuropathic pain characteristics and sleep disturbances [26].…”

Section: Tablementioning

confidence: 99%

“…In a study from Israel, assessing the relationship between symptom clusters and chemotherapy-induced neuropathic pain in a sample of 40 patients treated with paclitaxel, the authors found that the "high cluster group" included patients who reported both high levels of pain with neuropathic pain characteristics and sleep disturbances [26]. A study from Spain assessing patients for a median time of 18 months after cancer diagnosis, found that the pharmacological treatment of neuropathic pain was associated with an improvement in sleep quality eight weeks later [27]. In both studies, the identification of Inventory.…”

Section: Tablementioning

confidence: 99%

Neuropathic pain after breast cancer treatment and its impact on sleep quality one year after cancer diagnosis

et al. 2017

View full text Add to dashboard Cite

a b s t r a c tObjectives: Data regarding the impact of breast cancer treatment-related neuropathic pain (NP) on sleep quality are scarce. Therefore, we aimed to assess the impact of breast cancer treatment-related NP on patients' sleep quality, during the first year after cancer diagnosis. Materials and methods: A total of 501 breast cancer patients were followed prospectively. Incident NP was identified through systematic evaluations after treatments and one year after enrolment. NP severity was quantified using the Brief Pain Inventory severity subscale and sleep quality was evaluated through the Pittsburgh Sleep Quality Index (PSQI), at baseline and after one year. Adjusted regression coefficients (b) and 95% confidence intervals (95%CI) were used to quantify the relation between NP and the variation in the PSQI z-scores.

show abstract

“…27,58 Following radiotherapy, the prevalence of NP in oncology units is increased, leading to sleepiness, anxiety and depression. 59 Diagnostic or therapeutic surgery may lead to NCP, with incidence reaching high rates (60% to 90%) in some cases, such as after surgery for breast cancer, or after thoracotomy. 23,27 Postmastectomy pain syndrome is reported in about 20% of women, 60 may be particularly troublesome and could consequently affect patients' quality of life.…”

Section: 55mentioning

confidence: 99%

Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

et al. 2011

View full text Add to dashboard Cite

Neuropathic cancer pain (NCP), commonly encountered in clinical practice, may be cancer-related, namely resulting from nervous system tumor invasion, surgical nerve damage during tumor removal, radiation-induced nerve damage and chemotherapy-related neuropathy, or may be of benign origin, unrelated to cancer. A neuropathic component is evident in about 1/3 of cancer pain cases.Although from a pathophysiological perspective NCP may differ from chronic neuropathic pain (NP), such as noncancer-related pain, clinical practice, and limited publications have shown that these two pain entities may share some treatment modalities. For example, co-analgesics have been well integrated into cancer pain-management strategies and are often used as First-Line options for the treatment of NCP. These drugs, including antidepressants and anticonvulsants, are recommended by evidence-based guidelines, whereas, others such as lidocaine patch 5%, are supported by randomized, controlled, clinical data and are included in guidelines for restricted conditions treatment. The vast majority of these drugs have already been proven useful in the management of benign NP syndromes. Treatment decisions for patients with NP can be difficult. The intrinsic difficulties in performing randomized controlled trials in cancer pain have traditionally justified the acceptance of drugs already known to be effective in benign NP for the management of malignant NP, despite the lack of relevant high quality data. Interest in NCP mechanisms and pharmacotherapy has increased, resulting in significant mechanism-based treatment advances for the future. In this comprehensive review, we present the latest knowledge regarding NCP pharmacological management. n INTRODUCTIONFollowing EFIC's (European Federation of IASP Chapters) declaration in 2001, pain is not a symptom but a disease in its own right, necessitating appropriate treatment. The word pain usually refers to a discrete sensory experience, triggered by an identifiable set of ''painful'' stimuli, acting on a unique or stable ''pain'' pathway and eliciting an invariant sensation. However, pain, and particularly neuropathic pain (NP) can also exist as a diverse group of complex phenomena of unpleasant and distressing nature. NP encloses numerous complicated neurobiologic constituents and reflects potentially dynamic mechanisms, interacting at multiple neuraxial sites. 1Modern neurobiological techniques have led to tremendous progress in the exploration of pain pathogenetic mechanisms. [2][3][4] Research indicates that pain can be produced in multiple ways, at different locations, co-existing between and across various pathological conditions. 5,6 Novel therapeutic targets have been discovered and are used by the pharmaceutical industry for the construction of highly specific molecules, acting as potential innovative analgesics. Recent targets' application, specific to precise NP mechanisms, will very soon enable treatment to be focused at particular mechanisms, introducing a mechanism-based therap...

show abstract

Prevalence of Neuropathic Pain in Radiotherapy Oncology Units

Cited by 28 publications

References 56 publications

Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health

Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health

Neuropathic pain after breast cancer treatment and its impact on sleep quality one year after cancer diagnosis

Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature

Contact Info

Product

Resources

About